BioHorizons has introduced Prolifica, an allogeneic growth factor technology for its biomaterials portfolio, designed to support bone healing and tissue regeneration through an initial and sustained release of proteins.
BioHorizons has added Prolifica allogeneic growth factor technology to its biomaterials portfolio. The company describes Prolifica as a blend of allogeneic growth factors designed to support bone healing and tissue regeneration through a natural biphasic release of proteins. According to the announcement, the product delivers an initial release intended to support the initiation of the healing process, followed by a sustained release. BioHorizons said the technology retains at least 16 unique proteins associated with cell growth and biological processes involved in bone healing. Potential applications identified by the company include standalone bone grafting and grafting procedures performed with autologous or other allograft bone.

